Novo reportedly eyeing $1.09B investment in Brazil to expand obesity drug production

hapabapa/iStock Editorial via Getty Images Novo Nordisk ( NVO ) plans to invest 6.4B reais ($1.09B) in Brazil to boost the production of its highly popular diabetes/weight loss drugs Ozempic and Wegovy, as well as other injectables targeted at chronic diseases, Reuters reported Monday.

The construction work.